Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms and rectal biomarkers of immune activity

Valeria Castro Tejera1 | Lena Öhman2 | Lars Aabakken3 | Bengt Fellström4 | Trygve Hausken5 | Øistein Hovde6 | Johann P. Hreinsson1 | Greger Lindberg7 | Per Venge4,8 | Magnus Simrén1,9 | Hans Törnblom1

1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
3Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Norway
4Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden
5Department of Clinical Medicine, Haukeland University Hospital, University of Bergen, Bergen, Norway
6Department of Medicine, Innlandet Hospital Trust, Gjøvik, Norway
7Karolinska Institutet, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
8Diagnostics Development, Uppsala, Sweden
9Center for Functional GI and Motility Disorders, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA

Summary

Background: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS).

Aims: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa.

Methods: This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in subjects with IBS (Rome III criteria), with an eight-week treatment period of mesalazine 2400 mg or placebo once-daily. The primary endpoint was the global assessment of satisfactory relief of IBS symptoms in ≥50% of weeks during intervention. IBS symptoms were also measured with the IBS severity scoring system; immune activity was measured by mucosal patch technology. A post hoc meta-analysis of randomised placebo-controlled trials of mesalazine in IBS was added.

Results: Of 181 included patients, 91 received mesalazine and 90 received placebo. The primary endpoint was met by 32 (36%) patients after mesalazine and 27 (30%) after placebo (p = 0.40). There were no differences in response rates related to IBS subtype or post-infection symptom onset. More reduction of abdominal bloating was
1 | INTRODUCTION

Irritable bowel syndrome (IBS) is a functional bowel disorder, currently defined by the coexistence of abdominal pain and altered bowel habits that persist for at least 6 months, but without objective biomarkers. Although the disorder is not associated with increased mortality, it causes significant morbidity reflected by reduced quality of life, decreased work productivity and increased healthcare costs. Considering the high prevalence of IBS, there is a need for improved treatment options, even if there are good clinical guidelines to follow, based on predominant symptoms and a multidimensional clinical profile.

Our current understanding of IBS pathophysiology is that of a complex disorder with several interacting factors resulting in an aberrant bowel function where the number of factors that can be detected is associated with the intensity of IBS symptoms. No individual pathophysiological factor is universal, even if a bidirectionally disordered interaction between the gut and the brain has evolved as a central phenomenon. Among the putative pathophysiological mechanisms, a persisting low-grade immune activation in the gut has received much attention. The evidence comes from reports of gastrointestinal infections being the strongest risk factor for developing IBS and from a higher-than-expected rate of IBS-like symptoms in patients with inflammatory bowel disease in remission. This has fuelled interest in treatments aiming at dampening inflammatory mechanisms also in IBS. Disappointingly, neither treatments with prednisolone in patients with post-infection IBS nor treatment with mesalazine in patients suffering from IBS with diarrhoea (IBS-D) nor IBS including all subtypes was superior to placebo with symptom ratings as the outcome assessment, but with some indications of a favourable response in subsets of patients.

However, the identification of IBS patients predisposed to respond to anti-inflammatory treatment should potentially be based on the local immune activity in the gut rather than on the predominant bowel habit or mode of symptom onset. A small number of studies have used such an approach although with little success, as mucosal immune cell counts did not allow identification of IBS patients responding to anti-inflammatory treatment. Furthermore, faecal calprotectin is used for detecting and monitoring acute gastrointestinal inflammation among patients with inflammatory bowel disease, but is not sensitive enough to detect low-grade inflammation in IBS. The mucosal patch technology is potentially an alternative to measure local gut immune activity, showing noticeable difference in a subset of IBS patients when compared to healthy subjects. The mucosal patch technology was described as simple to use, safe and reliable, which together with the above-described need for a surrogate marker of low-grade gut immune activity fits well with a clinically useful tool to further our understanding about immunologic abnormalities in IBS and the effects of anti-inflammatory treatment.

In this study, we therefore tested the hypothesis that at least a subset of subjects with IBS respond clinically to anti-inflammatory treatment, and that this is associated with a specific immune activation profile at baseline and/or clear effect on gut immune activity. The primary study aim was to determine if mesalazine (Asacol) treatment was superior to placebo in improving IBS symptoms. The secondary aims were to investigate if improvement in specific IBS symptoms with mesalazine could be detected, and to establish if mucosal patch technology measures of immune activity in the rectal mucosa could identify specific IBS symptoms or patients more prone to respond to mesalazine treatment. As a post-hoc analysis, our data were added to a meta-analysis that included all randomised, double-blind, placebo-controlled trials (RCT) comparing the effect on IBS symptoms of mesalazine versus placebo.

2 | MATERIALS AND METHODS

2.1 | Study design and study population

This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in patients with IBS defined by the Rome III criteria. Two Swedish and three Norwegian hospitals participated in the recruitment of patients. The study included a 3-week screening period, an 8-week treatment period with oral mesalazine (Asacol, 800mg tablets, Tillotts Pharma AG) 2400mg once daily or matching placebo tablets (Tillotts Pharma AG) once daily (1:1 ratio), and a two-week safety follow-up period (Figure 1). At the screening visit, the patients were assessed for eligibility. The inclusion criteria were: Age ≥ 18 years, already diagnosed with IBS (Rome III criteria), IBS severity scoring system (IBS-SSS) ≥ 175, and having provided a signed informed consent to participate. All IBS subtypes were eligible for inclusion; IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and IBS with mixed bowel habits or unsubtyped IBS. Already prescribed IBS medications were allowed during the study if they had noted in the mesalazine group (p = 0.02). The meta-analysis showed no effect of mesalazine on IBS symptoms. No mucosal patch technology measure could predict response to mesalazine, and found no differences in the effects of intervention on levels of immune markers.

Conclusions: Mesalazine is ineffective in reducing IBS symptoms. Rectal measures of immune activity by the mucosal patch technology cannot predict a higher chance of response to mesalazine.
been used >3 months and at a stable dose. Exclusion criteria were: presence of a systemic inflammatory disease, other gastrointestinal disease likely to explain the IBS symptoms or other severe diseases as judged by the investigator; treatment with non-steroidal anti-inflammatory drugs, opioid analgesics or acetylsalicylic acid within 7 days prior to screening; treatment with antibiotics, immunosuppressive drugs or other significant medical treatment that could compromise the safety or efficacy objectives of the study within 28 days prior to screening; previously confirmed allergy towards mesalazine or acetylsalicylic acid; current infection; being pregnant or lactating; a history of or current drug or alcohol dependence; women of childbearing potential with unwillingness to use adequate contraceptive measures throughout the duration of the study. At visit 1, the screening visit, after the IBS-SSS questionnaire was completed, a review of the medical history and concomitant medication as well as a physical examination including vital signs was performed. A blood sample for analysis of haematology and clinical chemistry, a faecal sample for calprotectin, and in females of childbearing potential also a urine pregnancy test, was checked. Finally, the rectosigmoid colon was investigated with flexible sigmoidoscopy, and thereafter, a mucosal patch technology procedure was performed. At visit 2, the randomisation visit, the IBS-SSS questionnaire was once more completed, where the result still needed to be ≥175 to be eligible for randomisation into the intervention period, and the hospital anxiety and depression scale questionnaire was completed. After a symptom-directed physical evaluation including vital signs, the investigator assigned a consecutive randomisation number to the patient that corresponded to a study medication kit number available at the site and study medication was dispensed. The randomisation numbering of medication kits in blocks of four was done by use of a computer-generated list by the company providing mesalazine and placebo. The number code was kept confidential until after the end of the study and was broken after database lock. The patients were instructed to answer the weekly question about global symptom relief and complete the IBS-SSS questionnaire biweekly during the full intervention period. At visit 3 (day 28±2 after randomisation), a symptom-directed physical examination was performed if needed, vital signs checked, and a blood sample for analysis of haematology and clinical chemistry was taken. Study medication was reviewed for compliance and any adverse event was noted. At visit 4 (day 56±2 after randomisation), the end-of-treatment visit, a physical examination was performed, vital signs were checked, a blood sample for analysis of haematology and clinical chemistry was taken, and a faecal sample for calprotectin was collected. Remaining study medication was returned and reviewed for compliance and any adverse events were noted. Questionnaires on treatment satisfaction and IBS-SSS were collected, and the hospital anxiety and depression scale questionnaire was completed. Finally, the rectosigmoid colon was investigated for normality with flexible sigmoidoscopy, and thereafter, a mucosal patch technology procedure was performed. A telephone follow-up was done 2 weeks after the end of the intervention period to review any new adverse events or changes to pre-existing adverse events.

The study was conducted in accordance with the Declaration of Helsinki. All aspects of the study had been approved by Swedish and Norwegian Regional Ethical Review Boards (2011/1793–31/2, 2013/2032) and Medical Products agencies (2011–003418-18, 13/16072). The study was registered at ClinicalTrials.gov, identifier NCT01699438.

2.2 | Mucosal patch technology

The mucosal patch technology procedure for sampling of rectal mucosal fluid was done at the screening visit (visit 1) and at the end-of-treatment visit (visit 4). Before the mucosal patch technology procedure, a flexible sigmoidoscopy was performed to rule out rectosigmoid pathology. There was a separation in time between these investigations and randomisation to avoid procedure-related effects on IBS symptoms during the intervention period. The mucosal patch...
technology device consists of a plastic catheter with a silicon balloon at the end with three patches made of highly absorptive cellulose material attached on the balloon (Alimenta Medical AB). After positioning of the catheter in the rectum with the patient lying in the left lateral position with an intubation technique identical to rigid sigmoidoscopy, the balloon was inflated with 80 ml of air and kept inflated for 10 min. If the patient reported intolerable discomfort or pain intolerable, the volume of air was reduced in 5–10 ml steps until tolerated. Since the minimum volume assuring patches adhering to the rectal mucosa is 50 ml, the procedure was stopped if this volume could not be tolerated, or the patient otherwise judged the investigation to be intolerable. In those with a successful mucosal patch technology procedure, the instrument was retracted after balloon deflation, patches were cut off and placed in buffer solution in room temperature for 1 h. As last steps, the extraction solution was manually squeezed out of the patches, centrifuged at 2000–3000 g for 10 min and kept frozen at −80°C until analysis.

2.3 | Study assessments

2.3.1 | IBS symptom assessments

To assess the overall effect of the intervention, the patients were asked the following question on a weekly basis during the intervention period: “During the last week, have you experienced satisfactory relief of your IBS symptoms?”. In addition to this, the patient completed the IBS-SSS questionnaire at the screening and randomisation visits, and biweekly during the intervention period. This is a validated retrospective recall questionnaire for the assessment of IBS symptom severity. It includes four questions, intensity of abdominal pain, severity of abdominal bloating, dissatisfaction with bowel habits and the daily-life interference of IBS in general during the last week, for which answers are given on visual analogue scales (0–100). A fifth question, frequency (number of days) of abdominal pain during the last 10 days, is answered with the outcome multiplied by 10. IBS-SSS has a maximum aggregated score of 500. Severity is defined as moderate if the sum is ≥175 and severe if ≥300. It has been shown to be sensitive for assessment of a clinically relevant improvement of IBS symptoms if the reduction over time is ≥50.23

2.3.2 | Hospital anxiety and depression scale

This is a 14-item questionnaire measuring symptoms of anxiety and depression and intended for use in non-psychiatric populations.24 The maximum score is 21 on each of the two subscales. A higher score indicates higher levels of psychological distress within this specific domain.

2.3.3 | Markers of immune activity

From the mucosal patch technology extracts, the following analyses were performed: Myeloperoxidase and human neutrophil lipocalin as markers of neutrophil activity,25,26 eosinophil cationic protein as marker of eosinophil activity27 and human phospholipase B-precursor as marker of neutrophil and eosinophil activity and a non-specific epithelial cell factor.28 These were all measured by ELISA-kits provided by Diagnostics Development, Uppsala, Sweden. Tryptase measures were done by the Pharmacia ImmunoCAP assay to reflect mast cell activation. Faecal calprotectin was measured as a regular clinical assay at each study site according to the instructions given by the provider (Bühlmann Laboratories, Switzerland) and with lowest detection limit 15 mg/g.

2.4 | Compliance

The definition of satisfactory compliance to treatment was defined a priori as intake of ≥80% of the prescribed number of mesalazine/placebo doses. The medication was dispensed at visit 2 in identical packages labelled with a unique study ID and all packages were brought back to the hospital for medication count at visits 3 and 4.

2.5 | Data analysis and statistics

The global assessment of satisfactory relief of IBS-symptoms was used as the response parameter to define the primary endpoint. Response to treatment, that is, the primary endpoint, was defined as answering “yes” to the weekly question “During the last week, have you experienced satisfactory relief of your IBS symptoms” at least out of 8 weeks (≥50%). Two symptom-based secondary endpoints were used: response to treatment defined by giving the answer “yes” to the weekly question at least 6 out of 8 weeks (≥75%), or a reduction of IBS-SSS by ≥50 from randomisation (visit 2) to end of treatment (visit 4). Furthermore, both between- and within-group comparisons were made for the change in IBS-SSS and for the mucosal patch technology measures from visit 2 to visit 4. Finally, we also evaluated the response to treatment over time by use of the biweekly IBS-SSS data. All patients who received treatment after randomisation were included in the intention-to-treat analysis if any efficacy of response data was available. For the primary analysis, values of no symptom relief were imputed using the last-data-carried-forward principle when data was missing due to withdrawal. All patients who received treatment were also included in the safety population. With an expected 50% of patients in the mesalazine group and 30% of the patients in the placebo group achieving satisfactory symptom relief ≥50% of the time, the study needed to include 93 patients in each treatment group to detect a statistically significant difference between the two treatments on a 5% level with 80% power. With an expected 7% of patients being excluded from the primary analyses, a total of 200 patients were planned for randomisation.

Categorical data are summarised and presented as total numbers and percentages, with comparison between groups performed using the chi-squared test. Continuous data are presented as mean and standard deviation for symptom data (IBS-SSS) and demographics,
or as median with interquartile range for mucosal patch technology data. For comparisons of continuous data between the two treatment groups, the Mann–Whitney U-test was used, and for comparisons of mucosal patch technology data between IBS subtypes, the Kruskal–Wallis test was used. For all comparisons of paired samples of data, we used the Wilcoxon signed-rank test. Response to treatment over time was compared between mesalazine and placebo by use of repeated-measures ANOVA with treatment as independent variable and the symptom scores as outcome variable. Correlations between symptom scores and mucosal patch technology measures were determined with Spearman’s rank-order correlation. The statistical program SPSS version 27.0 (SPSS) was used for calculations. 

\( p \)-values less than 0.05 were used to define statistical significance.

### 2.6 Meta-analysis of randomised clinical trials comparing effects on IBS symptoms from mesalazine vs. placebo

A meta-analysis of previous randomised clinical trials\(^1\) and the current trial was undertaken using satisfactory relief of IBS symptoms as the endpoint. Data were pooled and analysed with a random-effects model. Statistical heterogeneity was evaluated using \( I^2 \) statistic. Differences were reported with standardised mean difference and values of 0.2–0.5 were considered small, 0.5–0.8 medium and >0.8 large. To represent satisfactory relief of IBS symptoms in studies with multiple endpoints, the endpoints abdominal pain, abdominal bloating, stool frequency, urgency and stool consistency were aggregated using the “MAd” package in R (version 4.0.3 – R Foundation, Vienna, Austria). Estimated correlation among within-study endpoints was set at 0.9. In studies with a categorical endpoint, odds ratios and their confidence intervals were converted to standardised mean differences as recommended in the Cochrane Handbook. These endpoints included global assessment of satisfactory relief of IBS symptoms ≥50% of weeks during intervention (current study), satisfactory relief of overall IBS symptoms in at least 50% of weeks over a three-month period and number of patients with satisfactory relief of IBS symptoms at 12 weeks.

### 3 RESULTS

The first patient entered the trial in July 2012 and the study was completed in January 2017. In total, 211 patients were screened for eligibility into the study until the study was stopped due to the study exceeding the funding period. Of these, 181 eligible IBS patients (70% females) were randomised and 90 received mesalazine 2400 mg/day and 91 received placebo. In total, 158 patients completed the entire intervention period and met the compliance criteria for the study medication. A study flow chart including screening failures and withdrawals from the study is outlined in Figure 2. The mean age for those randomised was 45.3 (range 20–72) years, where 28 (15%) had IBS-C, 72 (40%) had IBS-D and 81 (45%) had IBS with mixed bowel habits or unsubtyped IBS, without any difference in subtype distribution between the treatment groups. IBS severity was moderate in 69 (38%) patients and severe in 112 (62%) with a total range of IBS-SSS of 177–470. Demographics in the two treatment groups are summarised in Table 1. Both groups were comparable, except for a higher abdominal pain intensity in the placebo group, although the overall IBS symptom severity was similar.

#### 3.1 Effect on symptoms

##### 3.1.1 Primary endpoint

Satisfactory relief of IBS symptoms at least 50% of the weeks during treatment was reported by 32 (36%) patients in the mesalazine group compared to 27 (30%) in the placebo group (\( p = 0.40 \)). There

![FIGURE 2](image-url) Study flow chart. Disposition showing the number of patients assessed for eligibility, randomised, and patients completing the intervention. The non-gastrointestinal (GI) cancer was not diagnosed during study participation.
were no differences in response rates among IBS subtypes: IBS-C: 6 (46%) versus 6 (40%) ($p = 0.74$), IBS-D: 14 (38%) versus 11 (31%) ($p = 0.57$), or IBS with mixed bowel habits or unsubtyped IBS: 12 (30%) versus 10 (24%) ($p = 0.57$). A sudden or post-infection onset of the IBS symptoms, which was reported by 48 patients, did not influence the treatment outcome; 8 (32%) versus 7 (30%) of those subjects were classified as responders to mesalazine and placebo respectively ($p = 0.91$). Also, in the per-protocol analysis ($n = 158$), the outcome was similar between the groups receiving mesalazine and placebo: 32 (40%) versus 26 (33%) ($p = 0.38$).

### 3.1.2 | Secondary endpoints

The secondary endpoint, reporting satisfactory relief of IBS symptoms at least 75% of weeks during treatment, was reported by 15 (17%) patients in the mesalazine group and 16 (18%) in the placebo group ($p = 0.87$). The proportions of responders to treatment were similar also when a reduction in IBS-SSS $\geq 50$ was used as the response definition: 42 (47%) patients in the mesalazine group compared with 37 (42%) in the placebo group ($p = 0.45$). In both treatment groups, there was a significant improvement in IBS-SSS after the intervention period compared with baseline (mesalazine; baseline 319 (70) vs. after treatment 244 (107) (placebo; baseline 327 (72) vs. after treatment 270 (120), $p < 0.001$ for both). This was also noted for all the five individual IBS-SSS domains with similar improvements in both groups, except for abdominal bloating, where the improvement was greater in the mesalazine group than in the placebo group ($p = 0.02$), but other domains were similar in the treatment groups (Table 2). Both treatment groups showed a significant effect of time on IBS-SSS ($p < 0.001$), but there was no effect of the treatment ($p = 0.33$) and no time $\times$ treatment interaction effect ($p = 0.60$) indicating a similar symptom response during the 8-weeks intervention period regardless of time point. In both treatment groups, there was a significant improvement in symptoms of anxiety after the intervention period (mesalazine; baseline 7.3 (4.2) versus after treatment; 6.5 (3.7), $p = 0.04$, placebo; baseline 8.1 (4.1) vs 6.8 (4.0) $p < 0.001$), but without any difference between groups ($p = 0.61$). Depressive symptoms were unchanged in the mesalazine group (baseline 4.1 (3.1) vs after treatment; 3.9 (3.2), $p = 0.41$), but reduced in the placebo group (baseline 4.5 (3.4) vs after treatment 3.5 (3.2) $p < 0.001$), but without any difference between groups ($p = 0.39$).

### 3.2 | Markers of immune activity

The mucosal patch technology procedure was performed with complete results at the screening visit in 162 (90%) of the patients who were later randomised at visit 2, and at the end-of-the-treatment visit (visit 4) in 141 patients. In patients missing data from one or both mucosal patch technology procedures, this was due to intolerance to the procedure ($n = 5$), the equipment being temporarily unavailable during a part of the study period ($n = 12$), post-procedure handling of material that did not fulfil quality standards for reliable data outcome ($n = 7$) and the remaining for not finishing the study. Baseline measures of mucosal biomarkers in mucosal patch technology fluids did not differ between the two treatment groups (Table 3). Less than 10% of the samples had detectable tryptase.

### Table 1: Demographic data of the randomised subjects at baseline visit

|                          | Mesalazine (n = 90) | Placebo (n = 91) | p-value |
|--------------------------|---------------------|------------------|---------|
| Age, years (SD)          | 46.2 (14.2)         | 44.2 (14.9)      | 0.37    |
| Females, n (%)           | 64 (71)             | 63 (69)          | 0.79    |
| BMI (SD)                 | 25.1 (4.7)          | 24.5 (5.0)       | 0.42    |
| IBS-SSS, Total (SD)      | 319 (70)            | 327 (72)         | 0.47    |
| Abdominal pain intensity (SD) | 46 (25)           | 53 (24)          | 0.02    |
| Abdominal pain frequency (SD) | 66 (31)           | 70 (28)          | 0.44    |
| Abdominal bloating (SD)  | 62 (24)             | 60 (27)          | 0.71    |
| Dissatisfaction with bowel habit (SD) | 70 (23)    | 70 (23)          | 0.82    |
| General life interference (SD) | 75 (18)           | 75 (18)          | 0.80    |
| IBS-C, n (%)             | 13 (14)             | 15 (16)          | 0.90    |
| IBS-D, n (%)             | 37 (41)             | 35 (38)          |        |
| IBS-nonCnonD, n (%)      | 40 (44)             | 41 (45)          |        |
| Sudden onset, n (%)      | 25 (28)             | 23 (25)          | 0.70    |
| Anxiety, HAD (SD)        | 7.3 (4.2)           | 8.1 (4.1)        | 0.23    |
| Depression, HAD (SD)     | 4.1 (3.1)           | 4.5 (3.4)        | 0.46    |

Abbreviations: BMI, Body Mass Index; HAD, Hospital Anxiety and Depression scale; IBS-C, irritable bowel syndrome with constipation; IBS-D, irritable bowel syndrome with diarrhoea; IBS-nonCnonD, irritable bowel syndrome with mixed or unsubtyped bowel habit; IBS-SSS, Irritable bowel syndrome severity scoring system; SD, Standard deviation.
levels. When comparing the levels of the four mucosal biomarkers with measurable levels in the mucosal patch technology fluid, no difference could be noted based on IBS subtype. There were no correlations between the immune markers and IBS symptoms observed at baseline (Table 4).

Of the four immune markers measured by the mucosal patch technology, only human phospholipase B-precursor was reduced after the intervention, and this was seen in both the mesalazine and placebo groups. However, there were no differences between the intervention groups regarding the change in the immune markers before versus after treatment (Table 3). There were weak, but significant positive correlations between levels of human neutrophil lipocalin and severity of abdominal pain, severity of abdominal bloating, dissatisfaction with bowel habits and total IBS-SSS at the end of the treatment period, but for the other immunologic measures, no significant correlations to IBS symptoms were noted (Table 4). None of the immune measures at baseline differed between responders and non-responders to the treatment options (Table 5).

Faecal calprotectin measures were available in 178 patients of those randomised (98%), and in 153 patients who completed the study (97%). There were two and three patients in the mesalazine group, and three and two patients in the placebo group with a calprotectin level >100 g/mg at screening and at the end of study. None of these had signs of mucosal inflammation at sigmoidoscopy or signs of inflammation in blood tests. Since 70% of tests at the screening visit and 72% of tests at end of study were below the detection level, this immune parameter was not used for further analysis.

### 3.3 Adverse events

In total, 123 (68%) reported one or more adverse events (Table 6). The judged causality between treatment and adverse events was similar in the two treatment groups as were the number of patients that discontinued treatment because of adverse events.

One patient treated with mesalazine became pregnant during the trial and was therefore excluded. Another subject who received mesalazine treatment was diagnosed with a non-GI cancer after the trial start and excluded from analysis, although this was judged without causality to the treatment.

### 3.4 Meta-analysis of randomised clinical trials comparing effects on IBS symptoms from mesalazine vs. placebo

In the meta-analysis, the pooled standardised mean difference did not indicate any clear effect of mesalazine treatment or placebo.
The pooled standardised mean difference slightly favoured mesalazine (−0.07 [−0.21; 0.07]), but the estimate was close to zero and its confidence interval included both negative and positive values (Figure 3). The $I^2$ was 0%, indicating low heterogeneity.

### DISCUSSION

In this randomised, double-blind, placebo-controlled, multicentre trial, the effect of 8-weeks mesalazine treatment was not superior to placebo treatment for global improvement of IBS symptoms. Furthermore, no clear effects of mesalazine as compared with placebo were noted on individual IBS symptoms or gut immune activity measured by the mucosal patch technology, and gut immune activity measured with the mucosal patch technology could not predict the response to mesalazine treatment.
With the outcome of our study at hand supporting previous reports,\textsuperscript{17,18} the evidence that treatment with mesalazine for symptom relief in patients with IBS is ineffective is now convincing. We used a treatment period of 8 weeks, and two other major studies with negative outcome both had 12 weeks of treatment.\textsuperscript{17,18} With the current understanding of the disorders of gut–brain interaction,\textsuperscript{33} an even longer treatment period would perhaps be needed to fully rule out mesalazine treatment in IBS. However, none of the so far conducted studies has identified any tendencies suggesting that certain patient subsets would clearly benefit from long-term mesalazine treatment. This is further strengthened by our post-hoc meta-analysis of randomised clinical trials comparing effects on IBS symptoms from mesalazine versus placebo.\textsuperscript{17–19,29,30}

A justification for repeating a study of mesalazine in IBS would have been valid if we had identified a specific subgroup with immunologic activation with a more favourable treatment outcome. This fell short, both by prediction of outcome from pre-treatment levels of immunologic markers, and by not showing any significant effects comparing the change in immunologic markers between treatment groups. Now almost 20 years ago, when the suspicion of low-grade mucosal inflammation being a significant factor in the pathophysiology of IBS still was novel, a pioneering study in patients with post-infection IBS was presented, where the effects of 30 mg prednisolone/day for 3 weeks on IBS symptoms were evaluated in a randomised controlled design on 29 patients. No effect on symptoms was evident, but a reduction in mucosal lymphocyte count was noted after treatment.\textsuperscript{16} Later, in a proof-of-concept study including the effects of mesalazine treatment on colonic immune cell counts and IBS symptoms, the same pattern was noted, with a reduction in lymphocyte counts that was not accompanied by any discernible symptom-reducing effects compared with placebo.\textsuperscript{19} These data speak against the lymphocytes being the major immunologic factor to address in anti-inflammatory treatments in IBS. Added to this, several similar attempts have been made to find a niche of IBS patients responsive to treatment with mesalazine,\textsuperscript{12,18,29,30} all without success in defining any subgroup of relevance.

Our hypothesis that mucosal patch technology measures could provide one or more sensitive biomarkers of low-grade immune activity of relevance in IBS was based on the previous report of elevated levels of human neutrophil lipocalin and myeloperoxidase, potentially reflecting neutrophil activity, in a small IBS sample.\textsuperscript{21} In our current study, we noted a signal after treatment with levels of human neutrophil lipocalin weakly correlated with IBS symptom severity. However, no similar correlations were seen before the intervention, which makes the relevance of the post-intervention findings of correlations uncertain. Based on a rather convincing evidence that mast cell activity is of putative importance in the pathogenesis of IBS\textsuperscript{34} and also has been linked to the intensity of abdominal pain in a pivotal study,\textsuperscript{35} we aimed to measure tryptase levels in the mucosal patch technology fluids. Unfortunately, the mucosal patch technology procedure as used by us during this study was not able to detect tryptase in the analyses from most participants. Whether this depends on a flaw in any step of our protocol or reflects truly low levels cannot be answered with certainty. Considering the recent study that linked a mast cell-dependent mechanism to the development of visceral hypersensitivity after an inflammatory immune response,\textsuperscript{36} this aspect of the putative role of a local measure is still highly relevant and where methods like the mucosal patch technology could be useful. In this context, the time window and characteristics in relation to a putative infectious provocation in humans need further studies. We still do not know if tryptase activity is relevant for symptom progression over time in humans after visceral hypersensitivity has been established and the prerequisite of an IBS diagnosis of at least 6 months symptom duration is fulfilled.

Another positive finding from the mucosal patch technology measures, but with unclear relevance, is the reduced levels of human phospholipase B-precursor after the treatment period in both groups, but with no difference between the treatments. This phospholipase B-precursor is expressed in neutrophils, eosinophils and by gut epithelial cells,\textsuperscript{28,37} but with an unclear relation to disease that in theory could reflect both immune activity and some aspect of epithelial cell health. Fritcher-Ravens et al. reported in 2014...
that in IBS patients with suspected food intolerance, candidate food antigens caused rapidly occurring objective mucosal damage after local gut exposure in the form of epithelial leaks and gaps and widened intervillous spaces, observed by use of confocal laser endomicroscopy. It is tempting to speculate that human phospholipase B-precursor measured by the mucosal patch technology could be an alternative biomarker of gut mucosal integrity or "health", but as stated above, the relevance of our findings remains speculative. The rationale for exploring mesalazine in the treatment of a lymphocyte and mast cell predominant immune activation as reported in IBS was among other things motivated by the peroxisome proliferators-activated receptor-γ binding properties of mesalazine. Since peroxisome proliferators-activated receptor-γ is widely expressed on many cell types, including colonic epithelial cells, lamina propria T and B cells, and also mast cells, an effect of mesalazine on various immune cells can be expected, which may theoretically be advantageous in IBS, where different immune alterations have been suggested.

The major strength of our study is the number of participants and the randomised, double-blind, placebo-controlled design. Even if study recruitment was stopped prematurely and the number of dropouts was higher than expected, meaning that the study is formally underpowered, we can conclude that the results make it highly unlikely that we have missed a relevant role for mesalazine treatment in IBS in clinical practice, regardless of subtype or whether having characteristics of post-infection IBS. The multicentre recruitment also meant that the participants were representative for at least a Scandinavian adult population. The old definition of satisfactory relief of IBS symptoms can also be argued as clinically relevant, even if this is not being the current gold standard in pharmacological interventions in IBS patients. Since we also report on abdominal pain and dissatisfaction with bowel habit, we can conclude it as highly unlikely that the current recommended composite endpoint for pharmacologic interventions in IBS would have been met. The novel inclusion of biomarkers of rectal mucosal integrity and immune function also adds to the importance, even if the outcome is largely negative.

One weakness in any study design that includes invasive procedures, such as sigmoidoscopy and the mucosal patch technology procedure in our study, is that they can affect symptom reports. The possibility of anxiety affecting symptom intensity in the period before each measurement, but also for a period after each measurement, can also not be excluded. However, both treatment groups had similar baseline characteristics regarding psychological symptoms, and the randomised, double-blind, placebo-controlled design should prevent this from being a major limitation. We also believe that separating the screening visit where these investigations were done from the randomisation visit prevented post-procedural symptoms to affect baseline symptom reports.

To conclude, mesalazine is ineffective in reducing IBS symptoms after an 8-week treatment period. Mucosal patch technology measures are not able to detect biomarkers of immune activity that can predict a higher chance for response to mesalazine treatment.

AUTHOR CONTRIBUTIONS
Valeria Castro Tejera: Data curation (lead); formal analysis (equal); investigation (equal); project administration (equal); writing – original draft (lead). Lena Öhman: Conceptualization (supporting); formal analysis (supporting); investigation (supporting); methodology (supporting); project administration (supporting); writing – review and editing (equal). Lars Aabakken: Investigation (supporting); project administration (supporting); writing – review and editing (supporting). Bengt Fellström: Funding acquisition (supporting); investigation (supporting); methodology (supporting); writing – review and editing (supporting). Trygve Hausten: Investigation (supporting); project administration (supporting); writing – review and editing (supporting). Oistein Hovde: Investigation (supporting); project administration (supporting); writing – review and editing (supporting). Johann P Hreinsson: Formal analysis (supporting); methodology (supporting); writing – review and editing (supporting). Gregor Lindberg: Investigation (supporting); project administration (supporting); writing – review and editing (supporting). Per Venge: Conceptualization (supporting); data curation (equal); formal analysis (equal); funding acquisition (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Magnus Simrén: Conceptualization (equal); data curation (equal); formal analysis (equal); funding acquisition (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Hans Törnblom: Conceptualization (lead); data curation (equal); formal analysis (equal); funding acquisition (equal); methodology (equal); project administration (equal); supervision (lead); writing – original draft (supporting); writing – review and editing (lead).

ACKNOWLEDGEMENT
Declaration of personal interests: VCT, LA, GL and JPH declare no conflict of interest. LÖ has served as Consultant/Advisory Board member for Genetic Analysis AS, has received unrestricted research grants from AstraZeneca and as a speaker for Takeda, AbbVie and Meda. BF has served as Consultant for BMS, AstraZeneca, Calliditas, Pharmalink, Astellas, ALEXION, CSL Behring, SANDOZ, has ownership interest in Calliditas (<1%), has received research funding from BMS, Pharmalink, Astellas, SANDOZ, CSL Behring, has received honoraria from BMS, NOVARTIS, Sandoz, AstraZeneca, Roche, Calliditas, ALEXION, and has personal pending patent and Advisory or Leadership Role: Calliditas, Astellas, ALEXION, CSL Behring, Sandoz, BioAnalogica AB, Transcutan AB, BioConcept AB, ØH has served as Consultant/Advisory Board member/speaker for Jansen-Cilag. PV is the major owner of Diagnostics Development and owns worldwide patents of the immunoassay of human neutrophil lipocalin and phospholipase B-precursor. MS has received unrestricted research grants from Glycom and Danone Nutricia Research and served as advisory board member/consultant and/or speaker for Biocodex Glycom, Danone Nutricia Research, Ironwood, Genetic Analysis AS, Kyowa Kirin, Menarini, Arena, Adnovate, Tillotts, Takeda, Alimentary Health, AlfaSigma, Falk Foundation and Shire. HT has served as a speaker for Biocodex, Takeda and Tillotts.
REFERENCES

1. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Global burden of irritable bowel syndrome: results of a worldwide prevalence survey. Gastroenterology. 2014;146(2):309–20.

2. Staller K, Olen O, Soderling J, Roelstraete B, Tornblom H, Khalili H, et al. Mortality risk in irritable bowel syndrome: results from a Nationwide prospective cohort study. Am J Gastroenterol. 2020;115:746–55.

3. Chang CY, Locke GR III, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822–32.

4. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.

5. Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113(10):1540–9.

6. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473–86.

7. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–21 e4.

8. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99–114 e3.

9. Simren M, Tornblom H, Palsson OS, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2017;2(2):112–22.

10. Drossman DA, Ed S, Chang L, Chey WD, Kellow JE, Tack J, et al. Rome IV multidimensional clinical profile for the functional gastrointestinal disorders. 2nd ed. Raleigh, NC: The Rome Foundation; 2016.

11. Simren M, Tornblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology. 2019;157(2):391–402 e2.

12. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–61.

13. Barbara G, Grover M, Berck P, Corsetti M, Ghoshal UC, Ohman L, et al. Rome foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46–58 e7.

14. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(10):1474–82.

15. Jonetfjall B, Ohman L, Simren M, Strid H. IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being. Inflamm Bowel Dis. 2016;22(11):2630–40.

16. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Bogaonker M, Collins SM, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18(1):77–84.

17. Lam C, Tan W, Leighton M, Hastings M, Lingaya M, Falcone Y, et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut. 2016;65(1):91–9.

18. Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini M, et al. Randomised controlled trial of mesalazine in IBS. Gut. 2016;65(1):82–90.

19. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009;30(3):245–52.

20. Spiller R, Major G. IBS and IBD—separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol. 2016;13(10):613–21.

21. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut. 2004;53(12):1806–12.

22. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91.

23. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402.

24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.

25. Xu SY, Petersson CG, Carlson M, Venge P. The development of an assay for human neutrophil lipocalin (HNL)—to be used as a specific marker of neutrophil activity in vivo and vitro. J Immunol Methods. 1994;171(2):245–52.

26. Venge P. Monitoring the allergic inflammation. Allergy. 2004;59(1):26–32.

27. Metso T, Venge P, Haathela T, Peterson CG, Seveus L. Cell specific markers for eosinophils and neutrophils in sputum and bronchoalveolar lavage fluid of patients with respiratory conditions and healthy subjects. Thorax. 2002;57(5):449–51.

28. Xu S, Zhao L, Larsson A, Venge P. The identification of a phospholipase B precursor in human neutrophils. FEBS J. 2009;276(1):175–86.

29. Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC. Double-blind placebo-controlled study of mesalazine in post-infective irritable bowel syndrome—a pilot study. Scand J Gastroenterol. 2012;47(10):1159–64.

30. Ghadir MR, Poradineh M, Sotodeh M, Ansari R, Kolahdoozan S, Hormati A, et al. Mesalazine has no effect on mucosal immune biomarkers in patients with diarrhea-dominant irritable bowel syndrome referred to Shariati hospital: a randomized double-blind, placebo-controlled trial. Middle East J Digest Dis. 2017;9(1):20–5.

31. Del Re A, Hoyt W. MAAD: meta-analysis with mean differences. R package version 0.8-2. https://cran.r-project.org/package=MAAd. 2014.

32. Higgins JPT, Thomas J, editors. Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: John Wiley & Sons; 2019.
33. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–9.

34. Bashashati M, Moossavi S, Cremon C, Barbaro MR, Moraveji S, Talmon G, et al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(1):e13192.

35. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702.

36. Aguilera-Lizaraga J, Florens MV, Viola MF, Jain P, Decraecker L, Appeltans I, et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature. 2021;590(7844):151–6.

37. Xu S, Cai L, Zhao L, Douhan-Hakansson L, Kristjansson G, Pauksen K, et al. Tissue localization and the establishment of a sensitive immunoassay of the newly discovered human phospholipase B-precursor (PLB-P). J Immunol Methods. 2010;353(1–2):71–7.

38. Fritscher-Ravens A, Schuppan D, Ellrichmann M, Schoch S, Rocken C, Brusch J, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014;147(5):1012–20 e4.

39. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201(8):1205–15.

40. Dubuquoy L, Rousseaux C, Thur X, Peyrin-Biroulet L, Romano O, Chavatte P, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55(9):1341–9.

41. Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells; a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol. 2000;30(12):3363–70.

42. U.S. Department of Health and Human Services FdA, Center for Drug Evaluation and Research (CDER) Guidance for industry irritable bowel syndrome—clinical evaluation of products for treatment. 2012.